A Phase 4 interventional study of Human Chorionic Gonadotropin and human menopausal gonadotropin in Isolated Hypogonadotropic Hypogonadism, Kallmann Syndrome and Infertility, sponsored by Tongji Hospital. Recruiting at 1 site in China. Open to male participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2020-04-08.
Sponsored by Tongji Hospital · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will evaluate the efficacy and safety of long term use of hCG alone or hCG plus hMG in the treatment of male patients with isolated hypogonadotropic hypogonadism (IHH). One third of the participants will receive hCG treatment alone and the other third of the participants will receive hCG treatment alone for six months, then the hMG will be added. And the last third of the participants will receive hCG and hMG treatment since the beginning of the treatment.
The efficacy of hCG alone or hCG plus hMG in the treatment of male IHH patients was reported in some studies. However, these studies were mostly non-randomized controlled studies with small size of samples and short follow-up time. There was also no reported study which aimed to compare the efficacy and safety of long term use of hCG or hCG plus hMG in the treatment of male patients with IHH. So the difference in the efficacy and safety between long term use of hCG alone and hCG plus hMG in the treatment of IHH is unknown. In different reported studies, the hCG plus hMG treatment had two regimens: using hCG alone for six month, then hMG was added and using hCG plus hMG since the beginning of the treatment. The difference in the efficacy and safety between the above two regimes is also unknown.
23 studies on the registry are indexed under Kallmann Syndrome; 5 are open to participants now.
This study's planned enrollment of 210 is above the median of 75 across 14 interventional studies indexed under Kallmann Syndrome.
Browse Kallmann Syndrome studies →Tongji Hospital is the lead sponsor of 392 studies on the registry; 213 are open to participants now.
Compared within Kallmann Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hypogonadism. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Human Chorionic Gonadotropin 2000U\~6000U, intramuscular injection, two times per week for 3 years.
Drug: Human Chorionic Gonadotropin
Human Chorionic Gonadotropin 2000U\~6000U, intramuscular injection, two times per week for six months, then 75\~150IU human menopausal gonadotropin, intramuscular injection, two times per week, was added and last for the next 30 months.
Drug: Human Chorionic Gonadotropin · Drug: human menopausal gonadotropin
Human Chorionic Gonadotropin 2000U\~6000U and 75\~150IU human menopausal gonadotropin, intramuscular injection, two times per week for 3 years.
Drug: Human Chorionic Gonadotropin · Drug: human menopausal gonadotropin
White freeze-dried cake or powder with specifications of 1000U, 2000U, 5000U.
Also known as: hCG
White freeze-dried cake or powder with specification of 75IU.
Also known as: hMG
Sperm density
Sperm density will be obtained in the semen sample analysis using the World Health Organization (WHO) normal values based on the WHO 2010 reference limits.
Time frame: 6 months.
Semen volume
Sperm volume will be obtained in the semen sample analysis using the World Health Organization (WHO) normal values based on the WHO 2010 reference limits.
Time frame: 6 months.
Sperm activity
Sperm activity will be obtained in the semen sample analysis using the World Health Organization (WHO) normal values based on the WHO 2010 reference limits.
Time frame: 6 months.
The time for sperm to appear during treatment
The time for the sperm firstly appeared in the semen will be recorded.
Time frame: 6 months.
Serum testosterone levels
The serum testosterone levels will be tested in every visit.
Time frame: 3 months.
Testicular volume
Testicular volume will be measured using a Prader orchidometer.
Time frame: 3 months.
Penis length
Penis length will be measured from the pubic symphysis to glans using a vernier caliper.
Time frame: 3 months.
Pubic hair
Pubic hair will be evaluated according to Tanner pubertal stages.
Time frame: 3 months.
Genitalia
Genitalia will be evaluated according to Tanner pubertal stages.
Time frame: 3 months.
Height
Height will be measured at every visit.
Time frame: 3 months.
Weight
Weight will be measured at every visit.
Time frame: 3 months.
Feeling of inferiority scale score
Feeling of inferiority scale scores will be obtained using feeling of inferiority scale.
Time frame: 3 months.
Plan to share: Yes — De-identified individual participant data for all primary and secondary outcome measure will be available.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data will be available with 6 months of study completion.
Access criteria: Data access requests will be reviewed by the external independent review panel and Tongji hospital. Requester will be reqiured to sign a Data Acces Agreement.
Started Oct 2018 (actual). Primary completion is estimated for Oct 2024, 71 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Menotropins